SCHEMBL6888018

SCHEMBL6888018

CCc1nc2ccc(N3CCN4CCC3CC4)cc2c(=O)n1CC(=O)OC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 2/20 0.38
HDAC6 Q9UBN7 6/20 0.36
HDAC8 Q9BY41 3/20 0.36
HDAC1 Q13547 2/20 0.36
HDAC11 Q96DB2 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ALDH1A1 P00352 3/20 0.36
HDAC2 Q92769 1/20 0.34
KDM4E B2RXH2 2/20 0.34
USP2 O75604 1/20 0.34
TSHR P16473 1/20 0.34
PPARG P37231 1/20 0.34
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6887544 0.88 CHRNA7 (0.43) CHRNA7HDAC6HDAC8HDAC1HDAC11
SCHEMBL11922374 0.87 CHRNA7 (0.38) CHRNA7HDAC6HDAC8HDAC1HDAC11
SCHEMBL6888588 0.85 CHRNA7 (0.40) CHRNA7HDAC6HDAC8HDAC1HDAC11
SCHEMBL2459751 0.83 AVPR1B (0.41) CHRNA7CYP1A2CYP2C9CYP2C19
SCHEMBL6888343 0.83 CHRNA7 (0.40) CHRNA7HDAC6HDAC8HDAC1HDAC11
SCHEMBL6887587 0.82 CHRNA7 (0.38) CHRNA7HDAC6HDAC8HDAC1HDAC11
SCHEMBL6887911 0.82 AVPR1B (0.43) TSHRPPARG
SCHEMBL6888096 0.82 CHRNA7 (0.44) CHRNA7HDAC6HDAC8HDAC1HDAC11
SCHEMBL2463488 0.81 AVPR1A (0.38) CHRNA7CYP1A2CYP2C9CYP2C19
SCHEMBL6887450 0.81 CHRNA7 (0.43) CHRNA7HDAC6HDAC8HDAC1HDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8841289-B2 Heterocyclic derivatives MERCK SHARP & DOHME B.V. (US) 2014-09-23 US disclosed
US-8841289-B2 Heterocyclic derivatives MERCK SHARP & DOHME B.V. (US) 2014-09-23 US disclosed
US-20120208796-A1 HETEROCYCLIC DERIVATIVES ORGANON BIOSCIENCES NEDERLAND B.V. (NL) 2012-08-16 US disclosed
US-20120208796-A1 HETEROCYCLIC DERIVATIVES ORGANON BIOSCIENCES NEDERLAND B.V. (NL) 2012-08-16 US disclosed
WO-2011045258-A1 CONDENSED AZINE - DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE ACETYLCHOLINE RECEPTOR N.V. ORGANON (NL) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208796-A1 HETEROCYCLIC DERIVATIVES CHRNA5, CHRM5, CHRNA7 CHRNA7 3/4885HDAC6 482/4885HDAC8 913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.